• 1
    Takiyama Y, Oyanagi S, Kawashima S et al. A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology 1994; 44: 13021308.
  • 2
    Kanazawa I, Satoyoshi E, Hirayama K et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration. A multi-center double-blind comparative study with placebo. Rinsyo Iyaku 1997; 13: 41694224 (in Japanese).
  • 3
    Waragai M, Ogawara K, Takaya Y, Hayashi M. Efficacy of TRH-T for spinocerebellar degeneration: The relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku 1997; 37: 587594 (abstract) (in Japanese).
  • 4
    Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch. Neurol. 1995; 52: 982988.
  • 5
    Trouillas P, Xie J, Adeleine P et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch. Neurol. 1997; 54: 749752.
  • 6
    Trouillas P, Xie J, Adeleine P. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. Prog. Brain Res. 1997; 114: 589599.
  • 7
    Friedman JH. Machado-Joseph disease/Spinocerebellar ataxia 3. Responsive to Buspirone. Mov Disord. 1997; 12: 613614.
  • 8
    Saito Y, Miwa S, Yamana T, Hasegawa Y, Takagi S. Clinical therapeutical trial of oral tandospirone for cerebellar ataxia. Nagoya Shiritu Byouin Kiyou 1998; 21: 58. (in Japanese).
  • 9
    Nomoto M, Iwata S, Kaseda S, Mitsuda M, Shimizu T, Fukuda T. A 5-HT1A receptor agonist, tandospirone improves gait disturbance of patients with Parkinson's disease. Undo Syogai (J. Mov. Disord. Disability) 1997; 7: 6570 (in Japanese).
  • 10
    Trouillias P, Takayanagi T, Hallet M et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci. 1997; 145: 205211.
  • 11
    Zung WWK, Durham NC. A self-rating depression scale. Arch. Gen Psychiat. 1963; 12: 6370.
  • 12
    Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with laboratory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch. Neurol. 1988; 45: 12171222.
  • 13
    Trouillias P. L-5-Hydroxytryptophan treatment in hereditary and acquired ataxias. Mov Disord. 1990; 5 (Suppl. 1): 6.
  • 14
    Giordano J, Rogers L. Putative mechanisms of buspirone-induced antinociception in the rat. Pain 1992; 50: 365372.
  • 15
    Vickers SP, Clifton PG, Dourish CT. Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Psychopharmacology (Berl.) 1996; 125: 168175.
  • 16
    Sørensen E, Grønli J, Bjorvatn B, Bjørkum A, Ursin R. Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Res. 2001; 897: 122130.
  • 17
    Bjorvan B, Fagerland S, Eid T, Ursin R. Sleep/ waking effects of a selective 5-HT1A receptor agonist given systemically as well as perfused in the dorsal raphe nucleus in rats. Brain Res. 1997; 770: 81 88.
  • 18
    Darrow EJ, Strahlendorf HK, Strahlendorf JC. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonist 8-OH DPAT and ipsapirone in vitro. Eur. J. Pharmacol. 1990; 148: 235265.
  • 19
    Maura G, Reiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J. Neurochem. 1996; 66: 203209.